Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.
10.2147/OTT.S223406 Li et al. Onco Targets Ther
Li GZ, Zhang KN, Wang Z, Hu HM, Wang ZL, Huang RY, Jiang HY, Zhai Y, Feng YM, Chang YH, Li RP, Wu F, Zeng F, Jiang T, Zhang W
Study details